Abstract

LivaNova PLC will report first-quarter 2026 results on May 06, 2026 Pre-Market; this preview distills consensus forecasts, last quarter’s performance, and institutional perspectives on near-term drivers and risks.

Market Forecast

Consensus for the current quarter points to revenue of 346.11 million US dollars, an adjusted EPS of 0.90, and EBIT of 64.76 million US dollars, implying year-over-year growth of 14.48%, 17.62%, and 15.15%, respectively. Management margin guidance has not been disclosed in the dataset; the last reported gross margin was 66.74% and the last reported net margin was 8.56%, which frame investor expectations for this quarter’s profitability mix alongside the EPS forecast, whose implied year-over-year increase is 17.62%. The company’s portfolio is concentrated in two franchises: Cardiac Surgery and Neuromodulation. Investors expect stable demand in the core cardiac franchise and incrementally faster growth in Neuromodulation as programs broaden; Neuromodulation is viewed as the highest-upside segment near term, supported by a larger addressable population and expanding indications.

Last Quarter Review

LivaNova PLC delivered prior-quarter revenue of 360.90 million US dollars, with a gross margin of 66.74%, GAAP net profit attributable to the parent company of 30.91 million US dollars, a net margin of 8.56%, and adjusted EPS of 0.86, representing year-over-year growth of 12.15% for revenue and 6.17% for EPS. Revenue and EBIT both exceeded consensus modestly, with EBIT at 63.80 million US dollars and an earnings beat of 0.05 per share, demonstrating resilient operating execution against higher input and operating costs. The business mix continued to be led by Cardiac Surgery and Neuromodulation, which together accounted for the overwhelming share of revenue; sequentially, net profit grew by 15.39%, reflecting improved operating leverage.

Current Quarter Outlook

Core Cardiac Surgery

The near-term setup assumes continued stable procedure volumes and a supportive hospital capital environment for disposables and equipment across cardiac surgery. Order flow and utilization trends from the previous quarter suggest the franchise retains healthy share, while the 66.74% gross margin baseline puts cost absorption in a manageable range even as labor and logistics remain elevated. Key watch items are pacing in international markets and any pricing normalization, which could influence the mix and unit economics. If procedure throughput remains steady through April, revenue conversion should align with the 14.48% year-over-year company-level growth backdrop, while margin outcomes will depend on product mix across disposables and hardware.

Neuromodulation

Neuromodulation is positioned as the potential growth outlier this quarter given continued adoption in therapy indications and ongoing portfolio enhancements. The forecasted EPS growth of 17.62% versus revenue growth of 14.48% suggests operating leverage, and Neuromodulation’s contribution is important to sustaining this spread if utilization and patient throughput remain constructive. Reimbursement execution and access are pivotal variables; stable coverage and efficient referral pathways typically correlate with improved conversion from pipeline to treated patients. Investors will look for signs that therapy penetration continues to expand across centers, supporting mid-teens consolidated revenue growth while nudging EBIT toward the 15.15% year-over-year gain implied by consensus.

What May Drive the Stock This Quarter

Earnings sensitivity this print is most likely to come from the balance between revenue growth and gross-to-operating margin carry-through. If consolidated gross margin holds near the prior 66.74% and operating cost growth stays contained, the pathway to the projected 0.90 EPS is clear; deviation on mix or costs could move EPS materially given the modest spread between revenue and EBIT growth. Product and geography mix within Cardiac Surgery, along with incremental adoption signals in Neuromodulation, will influence investor reaction more than small absolute revenue variance. Finally, the cadence of new therapy utilization and any commentary on pipeline milestones can recalibrate second-quarter expectations and shape the multi-quarter trajectory embedded in institutional models.

Analyst Opinions

The balance of recent institutional commentary skews bullish, with most previews emphasizing execution consistency, improving operating leverage, and resilient demand in the cardiac and neuromodulation portfolios. Analysts highlighting the quarter cite the supportive setup of mid-teens revenue growth converging with mid-to-high-teens EPS growth, which collectively underpin the majority-positive stance. The constructive view centers on visibility into procedure volumes, reinforcement from the prior-quarter beat on revenue and EPS, and a forecasted EBIT increase of 15.15% year over year that signals healthy cost control into the print. Many institutional notes frame Neuromodulation as the incremental upside vector while acknowledging that price and mix within Cardiac Surgery remain important swing factors for margin. On balance, the bullish majority expects LivaNova PLC to deliver results that align with or modestly exceed consensus, with any upside likely driven by continued mix benefits and measured operating expense growth control.